TGA Fines Mundipharma over Opioid Advertisement

U.K.-based drugmaker Mundipharma was fined by Australia’s Therapeutic Goods Administration for a misleading claim in its oxycodone advertising.

The agency fined the drugmaker Aus$302,400 ($208, 610) over a claim in its promotional material for Targin (oxycodone). The advertisement, which was directed at healthcare professionals, encouraged the use of opioids in multimodal pain management plans.

“Opioids should not be represented as a core component of the multimodal management of chronic non-cancer pain, and the decision to prescribe opioids should be approached with significant caution,” TGA said.